Precision Coating offers medical coatings and application solutions, while N2 Biomedical provides nano-engineered surface treatment and coating services to the medical device industry
Precision Coating has announced merger with N2 Biomedical for medical coatings platform expansion. (Credit: bertholdbrodersen from Pixabay)
Medical coatings service provider Precision Coating has announced a merger with coating and surface treatment development and application services provider N2 Biomedical.
Precision Coating’s medical coatings and application solutions consists of GlideLine and InfiNiTiCoat coating products, which offer applied fluoropolymer (PTFE) coatings for interventional and advanced surgical devices.
Its MICRALOX portfolio offers aluminium anodising finishes for barrier properties, corrosion resistance, and extended product life cycles of orthopaedic and advanced surgical instruments.
By partnering with early-stage device innovators through major medical equipment manufacturers, the company provides flexible prototype work through high-volume coating application, finishing, and printing services.
Precision Coating, which serves customers across the world, has facilities in Massachusetts, Rhode Island, and Costa Rica.
Precision Coating president Bill Ellerkamp said: “We are very excited to add N2’s technologies and people to Precision Coating. N2 extends our coating platform technologies in ways that enhance our value proposition for customers.
“This is particularly true in orthopedics, where we can now offer engineered coating solutions across both instruments and implants.”
N2 Biomedical, an Ampersand Capital Partners portfolio company, offers nano-engineered surface treatment and coating services to the medical device industry with its low-temperature ion implantation surface treatments and ion beam assisted deposition (IBAD) technologies.
Founded in 2013, the company offers coating and surface treatment development and application services for implantable and other medical devices used in orthopaedic, cardiovascular and other healthcare end-markets.
The company has 27,000ft² facility with laboratory, manufacturing, and cleanroom space to meet all customer and regulatory requirements.
N2 Biomedical CEO Keith Edwards said: “The Precision Coating – N2 Biomedical merger pairs two firms with long histories of technology innovation, exceptional quality, continuous improvement, and a focus on supply performance.”
Under the deal, N2 Biomedical CEO Keith Edwards and CFO Heidi DeGrazia will join the Precision Coating executive leadership team.